表紙
市場調查報告書

低血壓症:開發中產品分析

Hypotension - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 465224
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
低血壓症:開發中產品分析 Hypotension - Pipeline Review, H2 2019
出版日期: 2019年08月30日內容資訊: 英文 54 Pages
簡介

當心跳數比平時低很多時,就會發生低血壓。屆時以心臟與腦為首,身體的其他部分將得不到充足的血液。症狀包括視力模糊,頭暈,混亂,失眠和虛弱。患者需要對症治療。

本報告提供低血壓症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

低血壓症;概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的開發中產品
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Anexon Inc
  • BCO Pharma Ltd
  • La Jolla Pharmaceutical Company
  • Theravance Biopharma Inc
  • TrioxBio Inc

藥物簡介

  • angiotensin II acetate
  • ANX-042
  • dopamine hydrochloride
  • MTR-105
  • MTR-107
  • TD-9855

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11356IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H2 2019, provides an overview of the Hypotension (Cardiovascular) pipeline landscape.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is required for patients with signs and symptoms.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypotension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Unknown stages are 2, 2, 1, 2 and 1 respectively.

Hypotension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypotension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypotension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypotension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypotension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypotension (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypotension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypotension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypotension - Overview
  • Hypotension - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Hypotension - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hypotension - Companies Involved in Therapeutics Development
    • Cerecor Inc
    • Handa Pharmaceuticals LLC
    • La Jolla Pharmaceutical Company
    • Theravance Biopharma Inc
    • TrioxBio Inc
  • Hypotension - Drug Profiles
    • ampreloxetine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • angiotensin II acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dopamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HND-024 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTR-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTR-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • phenylephrine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rislenemdaz - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hypotension - Dormant Projects
  • Hypotension - Product Development Milestones
    • Featured News & Press Releases
      • Jul 22, 2019: Theravance Biopharma reports new data from phase 2 study of ampreloxetine (TD-9855) in oral presentation at 32nd European Neurology Congress
      • Jun 28, 2019: La Jolla Pharmaceutical Company receives positive CHMP opinion for GIAPREZA (angiotensin II) for the treatment of refractory Hypotension in adults with septic or other distributive shock
      • Jun 18, 2019: Theravance Biopharma reports new data from phase 2 study of Ampreloxetine (TD-9855) in presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress
      • Jun 11, 2019: BrePco Biopharma announce the presentation of selected results of late-stage clinical trial in extremely premature neonates
      • Mar 25, 2019: Theravance Biopharma announces Ampreloxetine (TD-9855) phase 2 study results selected for oral presentation at 32nd European Neurology Congress
      • Jan 29, 2019: Theravance doses first patient in Phase III trial of ampreloxetine
      • Aug 01, 2018: Theravance Biopharma reports positive top-line four-week data from phase 2 trial of TD-9855 for the treatment of symptomatic neurogenic orthostatic hypotension
      • May 29, 2018: TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten for the Treatment of Intradialytic Hypotension
      • Sep 25, 2017: La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018
      • Sep 20, 2017: Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State
      • Aug 28, 2017: La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
      • Aug 08, 2017: La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501
      • May 21, 2017: Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
      • Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
      • Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hypotension, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Hypotension - Pipeline by Cerecor Inc, H2 2019
  • Hypotension - Pipeline by Handa Pharmaceuticals LLC, H2 2019
  • Hypotension - Pipeline by La Jolla Pharmaceutical Company, H2 2019
  • Hypotension - Pipeline by Theravance Biopharma Inc, H2 2019
  • Hypotension - Pipeline by TrioxBio Inc, H2 2019
  • Hypotension - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Hypotension, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top